title: The value of BP230 enzyme-linked immunosorbent assay in the diagnosis and immunological follow-up of bullous pemphigoid.
abstract: BACKGROUND
  The value of 230-kDa bullous pemphigoid antibody (BP230) enzyme-linked immunosorbent assay (ELISA) for the diagnosis of bullous pemphigoid (BP) was investigated, but in the immunological follow-up of the disease remains unknown.
  
  
  OBJECTIVE
  Evaluation of BP230 ELISA for diagnosis, follow-up and prediction of relapse in BP.
  
  
  METHODS
  Monocenter retrospective and prospective study. Patients with typical BP. Detection of autoantibodies by indirect immunofluorescence (IIF), BP180 and BP230 ELISA tests at diagnosis, during the treatment (disease control or failure) and at treatment stop (relapse or not 3 months after).
  
  
  RESULTS
  74 patients were included. At diagnosis, BP230 ELISA sensitivity was lower than IIF and BP180 ELISA. Combining both ELISA added a weak gain of sensitivity. Both tests paralleled the clinical evolution, especially in case of disease control. At the end of the treatment, BP230 ELISA was not different in patients with or without relapse.
  
  
  CONCLUSIONS
  In routine practice, BP230 ELISA does not seem to be a useful additional test in typical BP.
authors.affiliation: Department of Dermatology, Groupe Hospitalier Mondor, Créteil, France.
authors.forename: L
authors.initials: L
authors.lastname: Le Saché-de Peufeilhoux
authors.forename: S
authors.initials: S
authors.lastname: Ingen-Housz-Oro
authors.forename: S
authors.initials: S
authors.lastname: Hue
authors.forename: E
authors.initials: E
authors.lastname: Sbidian
authors.forename: L
authors.initials: L
authors.lastname: Valeyrie-Allanore
authors.forename: N
authors.initials: N
authors.lastname: Ortonne
authors.forename: J C
authors.initials: JC
authors.lastname: Roujeau
authors.forename: P
authors.initials: P
authors.lastname: Wolkenstein
authors.forename: O
authors.initials: O
authors.lastname: Chosidow
authors.forename: C
authors.initials: C
authors.lastname: André
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001323:Autoantibodies / Q000097:blood*; D002352:Carrier Proteins; D002990:Clobetasol / Q000627:therapeutic use; D003598:Cytoskeletal Proteins; D000071821:Dystonin; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D008562:Membrane Glycoproteins / Q000276:immunology*; D008727:Methotrexate / Q000627:therapeutic use; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D009419:Nerve Tissue Proteins; D010391:Pemphigoid, Bullous / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology*; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
chemical_list: D001323:Autoantibodies; D002352:Carrier Proteins; D003598:Cytoskeletal Proteins; C486268:DST protein, human; D000071821:Dystonin; D008562:Membrane Glycoproteins; D009419:Nerve Tissue Proteins; D002990:Clobetasol; D009173:Mycophenolic Acid; D008727:Methotrexate